Hereditary ovarian cancers: From BRCA mutations to clinical management. A modern appraisal

Andrea Tinelli, Antonio Malvasi, Giuseppe Leo, Daniele Vergara, Maurizio Pisanò, Mariangela Ciccarese, Vincenzo Emanuele Chiuri, Vito Lorusso

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

In the past few years, ovarian cancer research has focused increasingly on disease prevention; but an increasing number of women refer to gynecology and clinical genetics clinics with a family history of ovarian cancer and inherited familial mutations. The interest on the issue has increased also due to the identification of BReast CAncer1 (BRCA1) and BRCA2 genes mutations. The importance of recognizing the characteristics of hereditary ovarian cancer (HOC) and manage women at risk appropriately will provide more accurate care of the high-risk population. Women at risk can be identified by pedigree analysis and may receive counseling from interdisciplinary cancer genetics clinics, while those at high risk need to receive genetic testing. Risk calculation programs define risks and assist in decision-making in clinical options and genetic testing; they provide information on the risks of the disease, mutation status, and the use of genetic testing in the management of high-risk families. Furthermore, while a large number of surrogate preliminary markers have been identified, there are still limited studies on ovarian cancer genomics. Different options for risk management of HOC are available: surveillance, chemoprevention and prophylactic surgery. Surveillance in HOC high-risk patients is still not accurate. Chemoprevention is currently a controversial topic, because a number of major issues still need to be addressed in developing and testing agents for ovarian cancer chemoprevention. Prophylactic surgery has been shown to effectively decrease cancer risk, and it has the possibility to substantially reduce ovarian cancer mortality.

Original languageEnglish
Pages (from-to)339-350
Number of pages12
JournalCANCER AND METASTASIS REVIEW
Volume29
Issue number2
DOIs
Publication statusPublished - Jun 2010

Fingerprint

Ovarian Neoplasms
Mutation
Chemoprevention
Genetic Testing
Risk Management
BRCA2 Gene
Pedigree
Genomics
Gynecology
Counseling
Neoplasms
Breast
Biomarkers
Mortality
Research
Population

Keywords

  • BRCA
  • Counseling
  • Genetic testing
  • Genetics
  • Hereditary ovarian cancer
  • HNPCC
  • Laparoscopy
  • Oophorectomy
  • Prophylactic surgery
  • Risk assessment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Hereditary ovarian cancers : From BRCA mutations to clinical management. A modern appraisal. / Tinelli, Andrea; Malvasi, Antonio; Leo, Giuseppe; Vergara, Daniele; Pisanò, Maurizio; Ciccarese, Mariangela; Chiuri, Vincenzo Emanuele; Lorusso, Vito.

In: CANCER AND METASTASIS REVIEW, Vol. 29, No. 2, 06.2010, p. 339-350.

Research output: Contribution to journalArticle

Tinelli, A, Malvasi, A, Leo, G, Vergara, D, Pisanò, M, Ciccarese, M, Chiuri, VE & Lorusso, V 2010, 'Hereditary ovarian cancers: From BRCA mutations to clinical management. A modern appraisal', CANCER AND METASTASIS REVIEW, vol. 29, no. 2, pp. 339-350. https://doi.org/10.1007/s10555-010-9218-3
Tinelli, Andrea ; Malvasi, Antonio ; Leo, Giuseppe ; Vergara, Daniele ; Pisanò, Maurizio ; Ciccarese, Mariangela ; Chiuri, Vincenzo Emanuele ; Lorusso, Vito. / Hereditary ovarian cancers : From BRCA mutations to clinical management. A modern appraisal. In: CANCER AND METASTASIS REVIEW. 2010 ; Vol. 29, No. 2. pp. 339-350.
@article{fcc85b8fd10e41c698be0fe16696e151,
title = "Hereditary ovarian cancers: From BRCA mutations to clinical management. A modern appraisal",
abstract = "In the past few years, ovarian cancer research has focused increasingly on disease prevention; but an increasing number of women refer to gynecology and clinical genetics clinics with a family history of ovarian cancer and inherited familial mutations. The interest on the issue has increased also due to the identification of BReast CAncer1 (BRCA1) and BRCA2 genes mutations. The importance of recognizing the characteristics of hereditary ovarian cancer (HOC) and manage women at risk appropriately will provide more accurate care of the high-risk population. Women at risk can be identified by pedigree analysis and may receive counseling from interdisciplinary cancer genetics clinics, while those at high risk need to receive genetic testing. Risk calculation programs define risks and assist in decision-making in clinical options and genetic testing; they provide information on the risks of the disease, mutation status, and the use of genetic testing in the management of high-risk families. Furthermore, while a large number of surrogate preliminary markers have been identified, there are still limited studies on ovarian cancer genomics. Different options for risk management of HOC are available: surveillance, chemoprevention and prophylactic surgery. Surveillance in HOC high-risk patients is still not accurate. Chemoprevention is currently a controversial topic, because a number of major issues still need to be addressed in developing and testing agents for ovarian cancer chemoprevention. Prophylactic surgery has been shown to effectively decrease cancer risk, and it has the possibility to substantially reduce ovarian cancer mortality.",
keywords = "BRCA, Counseling, Genetic testing, Genetics, Hereditary ovarian cancer, HNPCC, Laparoscopy, Oophorectomy, Prophylactic surgery, Risk assessment",
author = "Andrea Tinelli and Antonio Malvasi and Giuseppe Leo and Daniele Vergara and Maurizio Pisan{\`o} and Mariangela Ciccarese and Chiuri, {Vincenzo Emanuele} and Vito Lorusso",
year = "2010",
month = "6",
doi = "10.1007/s10555-010-9218-3",
language = "English",
volume = "29",
pages = "339--350",
journal = "Cancer and Metastasis Reviews",
issn = "0167-7659",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Hereditary ovarian cancers

T2 - From BRCA mutations to clinical management. A modern appraisal

AU - Tinelli, Andrea

AU - Malvasi, Antonio

AU - Leo, Giuseppe

AU - Vergara, Daniele

AU - Pisanò, Maurizio

AU - Ciccarese, Mariangela

AU - Chiuri, Vincenzo Emanuele

AU - Lorusso, Vito

PY - 2010/6

Y1 - 2010/6

N2 - In the past few years, ovarian cancer research has focused increasingly on disease prevention; but an increasing number of women refer to gynecology and clinical genetics clinics with a family history of ovarian cancer and inherited familial mutations. The interest on the issue has increased also due to the identification of BReast CAncer1 (BRCA1) and BRCA2 genes mutations. The importance of recognizing the characteristics of hereditary ovarian cancer (HOC) and manage women at risk appropriately will provide more accurate care of the high-risk population. Women at risk can be identified by pedigree analysis and may receive counseling from interdisciplinary cancer genetics clinics, while those at high risk need to receive genetic testing. Risk calculation programs define risks and assist in decision-making in clinical options and genetic testing; they provide information on the risks of the disease, mutation status, and the use of genetic testing in the management of high-risk families. Furthermore, while a large number of surrogate preliminary markers have been identified, there are still limited studies on ovarian cancer genomics. Different options for risk management of HOC are available: surveillance, chemoprevention and prophylactic surgery. Surveillance in HOC high-risk patients is still not accurate. Chemoprevention is currently a controversial topic, because a number of major issues still need to be addressed in developing and testing agents for ovarian cancer chemoprevention. Prophylactic surgery has been shown to effectively decrease cancer risk, and it has the possibility to substantially reduce ovarian cancer mortality.

AB - In the past few years, ovarian cancer research has focused increasingly on disease prevention; but an increasing number of women refer to gynecology and clinical genetics clinics with a family history of ovarian cancer and inherited familial mutations. The interest on the issue has increased also due to the identification of BReast CAncer1 (BRCA1) and BRCA2 genes mutations. The importance of recognizing the characteristics of hereditary ovarian cancer (HOC) and manage women at risk appropriately will provide more accurate care of the high-risk population. Women at risk can be identified by pedigree analysis and may receive counseling from interdisciplinary cancer genetics clinics, while those at high risk need to receive genetic testing. Risk calculation programs define risks and assist in decision-making in clinical options and genetic testing; they provide information on the risks of the disease, mutation status, and the use of genetic testing in the management of high-risk families. Furthermore, while a large number of surrogate preliminary markers have been identified, there are still limited studies on ovarian cancer genomics. Different options for risk management of HOC are available: surveillance, chemoprevention and prophylactic surgery. Surveillance in HOC high-risk patients is still not accurate. Chemoprevention is currently a controversial topic, because a number of major issues still need to be addressed in developing and testing agents for ovarian cancer chemoprevention. Prophylactic surgery has been shown to effectively decrease cancer risk, and it has the possibility to substantially reduce ovarian cancer mortality.

KW - BRCA

KW - Counseling

KW - Genetic testing

KW - Genetics

KW - Hereditary ovarian cancer

KW - HNPCC

KW - Laparoscopy

KW - Oophorectomy

KW - Prophylactic surgery

KW - Risk assessment

UR - http://www.scopus.com/inward/record.url?scp=77954563347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954563347&partnerID=8YFLogxK

U2 - 10.1007/s10555-010-9218-3

DO - 10.1007/s10555-010-9218-3

M3 - Article

C2 - 20405170

AN - SCOPUS:77954563347

VL - 29

SP - 339

EP - 350

JO - Cancer and Metastasis Reviews

JF - Cancer and Metastasis Reviews

SN - 0167-7659

IS - 2

ER -